Ma Q, et al. - In this retrospective study involving 127 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), researchers compared the efficacy of two treatment regimens in double-hit lymphoma (DHL) and gene copy number gain (CNG) lymphoma: rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) vs traditional rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). They compared the prognosis of these two disease types. Genetic abnormalities in MYC, BCL2, and BCL6 were detected by using fluorescence in situ hybridization (FISH). R-DA-EPOCH regimen vs R-CHOP in double CNG patients was found to be significantly better, and R-DA-EPOCH displayed the same advantage in DHL patients. Findings revealed a poorer prognosis associated with DHL vs double CNG. R-DA-EPOCH offered improved lifetime and was well tolerated and, therefore, considered promising for DHL or double CNG.